Wide Ranks

LIPO

Lipella Pharmaceuticals Inc.

2.95

Top Statistics
Market Cap 3 M Forward PE -0.9219 Revenue Growth 27.90 %
Current Ratio 4.33 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA Enterprise / Revenue 2.63 Price To Sales Trailing12 Months 7.03
Profitability
Profit Margins 0.00 % Operating Margins -697.93 %
Balance Sheet
Total Cash 1 M Total Cash Per Share 1.19 Total Debt 93679
Total Debt To Equity 5.50 Current Ratio 4.33 Book Value Per Share 4.16
All Measures
Short Ratio 1.00 % Message Board Id finmb_35907207 Shares Short Prior Month 22482
Return On Equity -1.72 City Pittsburgh Uuid d39a1b66-6fea-3b6c-8773-cda09b9e9d93
Previous Close 2.80 First Trade Date Epoch Utc 1 B Book Value 4.16
Total Debt 93679 Volume 184182 Price To Book 0.7100
Last Split Date 1 B Fifty Two Week Low 2.21 Total Cash Per Share 1.19
Total Revenue 507204 Shares Short Previous Month Date 1 B Target Median Price 10.00
Max Age 86400 Recommendation Mean 2.00 Sand P52 Week Change 0.3133
Operating Margins -697.93 % Target Mean Price 10.00 Net Income To Common -4142409
Short Percent Of Float 0.0026 Implied Shares Outstanding 1 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 102400 Average Volume10days 102400
Total Cash 1 M Next Fiscal Year End 1 B Revenue Per Share 0.5920
Held Percent Insiders 0.2937 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 2.80 Target Low Price 10.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 3.18 Open 2.80
Free Cashflow -2254496 State PA Dividend Yield 0.00 %
Return On Assets -0.9377 Time Zone Short Name EST Trailing Eps -4.29
Day Low 2.65 Address1 7800 Susquehanna St. Shares Outstanding 1 M
Price Hint 4 Target High Price 10.00 Website https://www.lipella.com
52 Week Change -0.6737 Average Volume 169134 Forward Eps -3.20
Recommendation Key buy Compensation As Of Epoch Date 1 B Quick Ratio 254.40 %
Last Split Factor 1:8 Regular Market Day High 3.00 Is_sp_500 False
Profit Margins 0.00 % Debt To Equity 5.50 Fifty Two Week High 12.00
Day High 3.00 Shares Short 2273 Regular Market Open 2.80
Industry Key biotechnology Earnings Growth 0.00 % Enterprise To Revenue 2.63
Revenue Growth 27.90 % Shares Percent Shares Out 0.0019 Operating Cashflow -3724304
Currency USD Time Zone Full Name America/New_York Market Cap 3 M
Is_nasdaq_100 False Zip 15208 Quote Type EQUITY
Industry Biotechnology Long Name Lipella Pharmaceuticals Inc. Regular Market Day Low 2.65
Held Percent Institutions 0.0088 Current Price 2.95 Address2 Suite 505
Financial Currency USD Current Ratio 4.33 Industry Disp Biotechnology
Number Of Analyst Opinions 1 Country United States Float Shares 650777
Two Hundred Day Average 4.66 Enterprise Value 1 M Price To Sales Trailing12 Months 7.03
Forward PE -0.9219 Regular Market Volume 184182 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications.

The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD).

Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.